[go: up one dir, main page]

MX2013000958A - Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. - Google Patents

Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.

Info

Publication number
MX2013000958A
MX2013000958A MX2013000958A MX2013000958A MX2013000958A MX 2013000958 A MX2013000958 A MX 2013000958A MX 2013000958 A MX2013000958 A MX 2013000958A MX 2013000958 A MX2013000958 A MX 2013000958A MX 2013000958 A MX2013000958 A MX 2013000958A
Authority
MX
Mexico
Prior art keywords
plasma
manufacture
iaip
alpha
inter
Prior art date
Application number
MX2013000958A
Other languages
English (en)
Inventor
Sindhu Ramachandran
Shawn F Bairstow
Jennifer Hutsell
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of MX2013000958A publication Critical patent/MX2013000958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona composiciones y formulaciones farmacéuticas de IaIp derivadas de plasma. También se proporcionan los métodos para la elaboración de las composiciones y formulaciones de IaIp, así como los métodos para el tratamiento de las enfermedades asociadas con la disfunción por IaIp.
MX2013000958A 2010-07-23 2011-07-22 Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. MX2013000958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36733110P 2010-07-23 2010-07-23
PCT/US2011/045099 WO2012012773A1 (en) 2010-07-23 2011-07-22 Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma

Publications (1)

Publication Number Publication Date
MX2013000958A true MX2013000958A (es) 2013-11-20

Family

ID=44534634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000958A MX2013000958A (es) 2010-07-23 2011-07-22 Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.

Country Status (14)

Country Link
US (2) US8841248B2 (es)
EP (1) EP2596014B1 (es)
JP (1) JP5830096B2 (es)
KR (1) KR20130093607A (es)
CN (1) CN103119058A (es)
AU (1) AU2011280907B2 (es)
BR (1) BR112013001753A2 (es)
CA (1) CA2806645A1 (es)
CO (1) CO6680653A2 (es)
EA (1) EA201390156A1 (es)
ES (1) ES2717177T3 (es)
MX (1) MX2013000958A (es)
SG (1) SG187599A1 (es)
WO (1) WO2012012773A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CA2726281C (en) 2008-05-28 2023-04-18 Prothera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from blood
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
CA2885604A1 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of ischemia using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CA3036553A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
WO2018200722A1 (en) 2017-04-25 2018-11-01 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US20210393750A1 (en) * 2018-10-24 2021-12-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN114096558B (zh) * 2019-07-04 2024-10-01 德国杰特贝林生物制品有限公司 纯化c1-inh的方法
EP4126930A1 (en) * 2020-03-31 2023-02-08 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CN116322920A (zh) * 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
JP2023549538A (ja) 2020-11-16 2023-11-27 プロセラ バイオロジクス， インク． インターアルファインヒビタータンパク質の精製方法
WO2023215722A1 (en) * 2022-05-02 2023-11-09 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2711371B1 (fr) * 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
DE59509979D1 (de) * 1995-09-22 2002-02-07 Zlb Bioplasma Ag Bern Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
JP2004511492A (ja) 2000-10-13 2004-04-15 オクタファルマ　アクチェン　ゲゼルシャフト ビクニンを含む血漿画分、その調製方法、およびその使用
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
CA2726281C (en) 2008-05-28 2023-04-18 Prothera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from blood
US8304524B2 (en) * 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8841248B2 (en) 2010-07-23 2014-09-23 Baxter International Inc. Manufacture of inter-alpha-inhibitor (IaIp) from plasma

Also Published As

Publication number Publication date
JP2013535468A (ja) 2013-09-12
AU2011280907A1 (en) 2013-02-07
KR20130093607A (ko) 2013-08-22
ES2717177T3 (es) 2019-06-19
EA201390156A1 (ru) 2014-01-30
US20120053113A1 (en) 2012-03-01
SG187599A1 (en) 2013-03-28
CO6680653A2 (es) 2013-05-31
EP2596014A1 (en) 2013-05-29
US8841248B2 (en) 2014-09-23
CA2806645A1 (en) 2012-01-26
AU2011280907B2 (en) 2016-02-04
US20150045538A1 (en) 2015-02-12
WO2012012773A1 (en) 2012-01-26
EP2596014B1 (en) 2018-11-28
JP5830096B2 (ja) 2015-12-09
BR112013001753A2 (pt) 2016-05-31
US9505814B2 (en) 2016-11-29
CN103119058A (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MY172292A (en) Vectors and sequences for the treatment of diseases
MD20150091A2 (ro) Compuşi antivirali
CA2871471C (en) Dna-pk inhibitors
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
JO3156B1 (ar) ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
MX349004B (es) Nuevos compuestos.
MX2013013913A (es) Polipeptidos.
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
EP3626253A3 (en) Stable formulations of linaclotide
MX2013010898A (es) Novedoso derivados de la pirimidina.
WO2012119070A3 (en) Silicone-based ophthalmic formulations
PH12014501991B1 (en) Phenicol antibacterials
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
IN2014DN03010A (es)
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal